Lecturer, Pathology, Tufts Medical Center
Hematology
Dr. Raymond L. Comenzo, MD
|
|
Give Review
Raymond L. Comenzo practices Hematology. He graduated from Boston University School of Medicine. Boston University School of Medicine is ranked 30 in research and 52 in primary care medicine He has 4 awards "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer" and "Super Doctor". Raymond Comenzo is a published doctor. He published 40 publications, including: 'Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.' He is registered with Medicare and accepts Medicare payments.
Publications
- Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
- Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
- Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium.
- Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed Systemic AL amyloidosis.
- Plasma Cell Neoplasms, Their Precursor States, and Their Prediction of Organ Damage.
- Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis.
- One siRNA pool targeting the λ constant region stops λ light chain proDuction and causes terminal endoplasmic reticulum stress.
- New Insights and Modern Treatment of AL Amyloidosis.
- Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity ...
- Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients With newly diagnosed light-chain amyloidosis.
- Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.
- Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer C...
- Plasma cell Leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
- The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells.
- Clinical and Echocardiographic Correlates of Elevated Troponin in Amyloid Light-Chain Cardiac Amyloidosis.
- Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis.
- Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients With newly diagnosed multiple myel...
- Who knows how to treat Systemic light chain amyloidosis?
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed Systemic AL amyloidosis: results of a phase 1/2 study.
- Renal impairment in patients With multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
- Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
- Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
- How I treat amyloidosis.
- Frequencies and types of arrhythmias in patients with Systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monit...
- International Myeloma Working Group guidelines for serum-free light chain Analysis in multiple myeloma and related disorders.
- CD32B is highly expressed on clonal plasma cells from patients with Systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.
- Calreticulin expression in the clonal plasma cells of patients with Systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.
- High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
- Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).
- Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego).
- Managing Systemic light-chain amyloidosis.
- Systemic immunoglobulin light-chain amyloidosis.
- Seeking confidence in the diagnosis of Systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.
- Amyloidosis.
- Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element.
- Expression of Cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and ...
- Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination.
- Autologous stem cell transplantation for primary Systemic amyloidosis.
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Schools
Boston University School Of Medicine
Boston City Hospital
New England Med Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Emblem Health
- Fallon Community Health Plan
- Harvard Pilgrim Health Care PPO
- Medicare Advantage PFFS
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Network Health
- PHP-Physicians Health Plan
- Simplifi
- Tufts Health Plans
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Tufts Medical Center -
Boston University Medical Center -
Boston University School of Medicine
Hospital
-
Tufts Medical Center
Drug Facts
| NPI NUMBER | 1750352787 | |
| NPPES Provider LastName | COMENZO | |
| NPPES Provider FirstName | RAYMOND | |
| NPPES Provider ZIPCode | 021111552 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology | |
| Total Claim Count | 245.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1750352787 |
| Last Name Of The Provider | COMENZO |
| First Name Of The Provider | RAYMOND |
| View All |
Similar Doctors
|
|
Dr. Aparna Raj, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ankur K. Nagaraja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin L. Schlechter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cindy Varga, MD |
|
|
Dr. David C. Park, MD |
|
|
Dr. Jacalyn M. Rosenblatt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elisabeth M. Battinelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lowell E. Schnipper, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Gabriela Motyckova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beverly Moy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy P. Cooley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert S. Meehan, MD |
|
|
Dr. Alfred I. Tauber, MD
This Doctor is OpenDoctor Recommended.
|